

# Kimme L Hyrich

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1553502/publications.pdf>

Version: 2024-02-01

239  
papers

10,853  
citations

26610

56  
h-index

37183

96  
g-index

240  
all docs

240  
docs citations

240  
times ranked

10649  
citing authors

#	ARTICLE	IF	CITATIONS
1	Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 859-866.	0.5	908
2	Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. <i>Rheumatology</i> , 2011, 50, 124-131.	0.9	564
3	Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 930-942.	0.5	496
4	Outcomes after switching from one anti-tumor necrosis factor agent to a second anti-tumor necrosis factor agent in patients with rheumatoid arthritis: Results from a large UK national cohort study. <i>Arthritis and Rheumatism</i> , 2007, 56, 13-20.	6.7	379
5	EULAR definition of difficult-to-treat rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 31-35.	0.5	224
6	Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 583-589.	0.5	188
7	BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. <i>Rheumatology</i> , 2010, 49, 2217-2219.	0.9	187
8	Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature. <i>Arthritis Research and Therapy</i> , 2016, 18, 251.	1.6	177
9	Persistence with anti-tumor necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. <i>Arthritis Research and Therapy</i> , 2009, 11, R52.	1.6	173
10	Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries. <i>Lancet Rheumatology</i> , The, 2020, 2, e250-e253.	2.2	172
11	Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1087-1093.	0.5	162
12	Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 823-826.	0.5	154
13	Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1137-1146.	0.5	151
14	Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 386-391.	0.5	150
15	Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 229-234.	0.5	146
16	Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 as a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis. <i>PLoS Genetics</i> , 2013, 9, e1003394.	1.5	146
17	Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. <i>Arthritis and Rheumatism</i> , 2011, 63, 645-653.	6.7	143
18	<i>HLA-DRB1*11</i> and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 15970-15975.	3.3	139

#	ARTICLE	IF	CITATIONS
19	Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register. <i>Arthritis and Rheumatism</i> , 2006, 54, 1786-1794.	6.7	136
20	Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 695-709.	0.5	130
21	Validity of a three-variable Juvenile Arthritis Disease Activity Score in children with new-onset juvenile idiopathic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1983-1988.	0.5	126
22	Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 654-660.	0.5	122
23	Rheumatic disease and COVID-19: epidemiology and outcomes. <i>Nature Reviews Rheumatology</i> , 2021, 17, 71-72.	3.5	120
24	Association of HLA-DRB1 Haplotypes With Rheumatoid Arthritis Severity, Mortality, and Treatment Response. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1645.	3.8	119
25	Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1405-1412.	0.5	117
26	Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. <i>Rheumatology</i> , 2013, 52, 91-98.	0.9	116
27	The incidence of rheumatoid arthritis in the UK: comparisons using the 2010 ACR/EULAR classification criteria and the 1987 ACR classification criteria. Results from the Norfolk Arthritis Register. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1315-1320.	0.5	116
28	Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2017-212825.	0.5	115
29	Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. <i>Rheumatology</i> , 2010, 49, 697-705.	0.9	112
30	The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 869-874.	0.5	107
31	EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 20-33.	0.5	104
32	Biologic therapies and pregnancy: the story so far. <i>Rheumatology</i> , 2014, 53, 1377-1385.	0.9	99
33	Rheumatoid arthritis risk allele <i>PTPRC</i> is also associated with response to anti-tumor necrosis factor $\pm$ therapy. <i>Arthritis and Rheumatism</i> , 2010, 62, 1849-1861.	6.7	95
34	Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. <i>Rheumatology</i> , 2015, 54, 494-499.	0.9	90
35	Juvenile idiopathic arthritis. <i>Nature Reviews Disease Primers</i> , 2022, 8, 5.	18.1	90
36	Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 497-503.	0.5	88

#	ARTICLE	IF	CITATIONS
37	Response to: "Correspondence on "Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry" by Mulhearn et al. Annals of the Rheumatic Diseases, 2023, 82, e116-e116.	0.5	87
38	Disease activity and disability in children with juvenile idiopathic arthritis one year following presentation to paediatric rheumatology. Results from the Childhood Arthritis Prospective Study. Rheumatology, 2010, 49, 116-122.	0.9	86
39	Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. JAMA Network Open, 2021, 4, e2129639.	2.8	86
40	The relationship between depression and biologic treatment response in rheumatoid arthritis: An analysis of the British Society for Rheumatology Biologics Register. Rheumatology, 2018, 57, 835-843.	0.9	83
41	Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey. Annals of the Rheumatic Diseases, 2018, 77, 1705-1709.	0.5	83
42	Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology, 2018, 57, 997-1001.	0.9	82
43	Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register. Arthritis Care and Research, 2012, 64, 1108-1115.	1.5	81
44	Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumor necrosis factor therapy for rheumatoid arthritis between 2001 and 2008. Rheumatology, 2011, 50, 117-123.	0.9	77
45	Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project. Annals of the Rheumatic Diseases, 2017, 76, 2025-2030.	0.5	77
46	Biologic Therapy for Rheumatoid Arthritis. BioDrugs, 2009, 23, 111-124.	2.2	75
47	Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology, 2010, 49, 1570-1577.	0.9	73
48	Malignancy and rheumatoid arthritis: Epidemiology, risk factors and management. Best Practice and Research in Clinical Rheumatology, 2018, 32, 869-886.	1.4	73
49	Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS). Arthritis Research and Therapy, 2018, 20, 147.	1.6	73
50	No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register. Arthritis and Rheumatism, 2010, 62, 3145-3153.	6.7	72
51	Different Methods of Balancing Covariates Leading to Different Effect Estimates in the Presence of Effect Modification. American Journal of Epidemiology, 2009, 169, 909-917.	1.6	71
52	The influence of behavioural and psychological factors on medication adherence over time in rheumatoid arthritis patients: a study in the biologics era. Rheumatology, 2015, 54, 1780-1791.	0.9	69
53	Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug. Rheumatology, 2008, 47, 1000-1005.	0.9	67
54	Effectiveness of Rituximab in Patients with Rheumatoid Arthritis: Observational Study from the British Society for Rheumatology Biologics Register. Journal of Rheumatology, 2012, 39, 240-246.	1.0	67

#	ARTICLE	IF	CITATIONS
55	The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis. <i>Rheumatology</i> , 2016, 55, 2033-2039.	0.9	67
56	Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients. <i>Rheumatology</i> , 2011, 50, 189-195.	0.9	62
57	Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1831-1834.	0.5	62
58	How common is remission in juvenile idiopathic arthritis: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 331-337.	1.6	60
59	Differential Methylation as a Biomarker of Response to Etanercept in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1353-1360.	2.9	59
60	Trends in paediatric rheumatology referral times and disease activity indices over a ten-year period among children and young people with Juvenile Idiopathic Arthritis: results from the childhood arthritis prospective Study. <i>Rheumatology</i> , 2016, 55, 1225-1234.	0.9	54
61	Depressive symptoms, pain and disability for adolescent patients with juvenile idiopathic arthritis: results from the Childhood Arthritis Prospective Study. <i>Rheumatology</i> , 2018, 57, 1381-1389.	0.9	52
62	Biologics registers in RA: methodological aspects, current role and future applications. <i>Nature Reviews Rheumatology</i> , 2017, 13, 503-510.	3.5	51
63	Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity. <i>Rheumatology</i> , 2009, 48, 1323-1327.	0.9	50
64	Profiling of Gene Expression Biomarkers as a Classifier of Methotrexate Nonresponse in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 678-684.	2.9	50
65	BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. <i>Rheumatology</i> , 2010, 49, 1197-1199.	0.9	49
66	High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 208-213.	0.5	49
67	Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 970-978.	0.5	49
68	Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the JAK-pot collaboration. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1358-1366.	0.5	48
69	2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 476-479.	0.5	47
70	Update on the epidemiology, risk factors and disease outcomes of Juvenile idiopathic arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 206-222.	1.4	47
71	Medically Significant Infections Are Increased in Patients With Juvenile Idiopathic Arthritis Treated With Etanercept: Results From the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. <i>Arthritis and Rheumatology</i> , 2015, 67, 2487-2494.	2.9	45
72	Patterns of pain over time among children with juvenile idiopathic arthritis. <i>Archives of Disease in Childhood</i> , 2018, 103, 437-443.	1.0	45

#	ARTICLE	IF	CITATIONS
73	Differential DNA methylation correlates with response to methotrexate in rheumatoid arthritis. <i>Rheumatology</i> , 2020, 59, 1364-1371.	0.9	43
74	How common is clinically inactive disease in a prospective cohort of patients with juvenile idiopathic arthritis? The importance of definition. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1381-1388.	0.5	42
75	Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritis. <i>Pharmacogenomics Journal</i> , 2018, 18, 657-664.	0.9	41
76	Psychological factors predict adherence to methotrexate in rheumatoid arthritis; findings from a systematic review of rates, predictors and associations with patient-reported and clinical outcomes. <i>RMD Open</i> , 2016, 2, e000171.	1.8	40
77	Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2017, 36, 241-250.	1.0	40
78	Prediction of infection risk in rheumatoid arthritis patients treated with biologics: are we any closer to risk stratification?. <i>Current Opinion in Rheumatology</i> , 2019, 31, 285-292.	2.0	39
79	Factors associated with choice of biologic among children with Juvenile Idiopathic Arthritis: results from two UK paediatric biologic registers. <i>Rheumatology</i> , 2016, 55, 1556-1565.	0.9	38
80	Long-term persistence of TNF-inhibitor treatment in patients with psoriatic arthritis. Data from the British Society for Rheumatology Biologics Register. <i>RMD Open</i> , 2018, 4, e000596.	1.8	38
81	Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study. <i>Lancet Rheumatology</i> , The, 2021, 3, e855-e864.	2.2	38
82	Efficacy of biologic therapy across individual juvenile idiopathic arthritis subtypes: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 46, 584-593.	1.6	37
83	SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry. <i>RMD Open</i> , 2022, 8, e002187.	1.8	34
84	Agreement between Proxy and Adolescent Assessment of Disability, Pain, and Well-Being in Juvenile Idiopathic Arthritis. <i>Journal of Pediatrics</i> , 2011, 158, 307-312.	0.9	33
85	Influence of anti-TNF patient warning regarding avoidance of high risk foods on rates of listeria and salmonella infections in the UK. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 461-462.	0.5	33
86	Factors associated with improvement in disease activity following initiation of etanercept in children and young people with Juvenile Idiopathic Arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. <i>Rheumatology</i> , 2016, 55, 840-847.	0.9	33
87	Malignancy and mortality rates in patients with severe psoriatic arthritis requiring tumour-necrosis factor alpha inhibition: results from the British Society for Rheumatology Biologics Register. <i>Rheumatology</i> , 2019, 58, 80-85.	0.9	33
88	Factors Associated With Sustained Remission in Rheumatoid Arthritis in Patients Treated With Anti-“Tumor Necrosis Factor. <i>Arthritis Care and Research</i> , 2017, 69, 783-793.	1.5	32
89	Anti-TNF therapy in women with rheumatoid arthritis with a history of carcinoma in situ of the cervix: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 143-144.	0.5	30
90	Biologic treatment response among adults with juvenile idiopathic arthritis: results from the British Society for Rheumatology Biologics Register. <i>Rheumatology</i> , 2013, 52, 1905-1913.	0.9	30

#	ARTICLE	IF	CITATIONS
91	SARS-CoV-2 infection after vaccination in patients with inflammatory rheumatic and musculoskeletal diseases. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 145-150.	0.5	30
92	Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA. <i>RMD Open</i> , 2017, 3, e000314.	1.8	29
93	Long-Term Outcomes Following Achievement of Clinically Inactive Disease in Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 1519-1529.	2.9	28
94	Recent developments in disease activity indices and outcome measures for juvenile idiopathic arthritis. <i>Rheumatology</i> , 2013, 52, 1941-1951.	0.9	27
95	A survey of national and multi-national registries and cohort studies in juvenile idiopathic arthritis: challenges and opportunities. <i>Pediatric Rheumatology</i> , 2017, 15, 31.	0.9	27
96	Use and effectiveness of rituximab in children and young people with juvenile idiopathic arthritis in a cohort study in the United Kingdom. <i>Rheumatology</i> , 2019, 58, 331-335.	0.9	27
97	Influence of past breast feeding on pattern and severity of presentation of juvenile idiopathic arthritis. <i>Archives of Disease in Childhood</i> , 2016, 101, 348-351.	1.0	26
98	Growth patterns in early juvenile idiopathic arthritis: Results from the Childhood Arthritis Prospective Study (CAPS). <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 53-60.	1.6	26
99	Predictors, demographics and frequency of sustained remission and low disease activity in anti-tumour necrosis factor-treated rheumatoid arthritis patients. <i>Rheumatology</i> , 2019, 58, 2162-2169.	0.9	26
100	Frequency of biologic switching and the outcomes of switching in children and young people with juvenile idiopathic arthritis: a national cohort study. <i>Lancet Rheumatology, The</i> , 2020, 2, e217-e226.	2.2	25
101	Patients with suspected rheumatoid arthritis should be referred early to rheumatology. <i>BMJ: British Medical Journal</i> , 2008, 336, 215-216.	2.4	24
102	Polypharmacy is associated with treatment response and serious adverse events: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Rheumatology</i> , 2019, 58, 1767-1776.	0.9	24
103	The Association Between Low Socioeconomic Status With High Physical Limitations and Low Illness Self-Perception in Patients With Juvenile Idiopathic Arthritis: Results From the Childhood Arthritis Prospective Study. <i>Arthritis Care and Research</i> , 2015, 67, 382-389.	1.5	23
104	Treatment prescribing patterns in patients with juvenile idiopathic arthritis (JIA): Analysis from the UK Childhood Arthritis Prospective Study (CAPS). <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 190-195.	1.6	23
105	Predicting disease outcomes in juvenile idiopathic arthritis: challenges, evidence, and new directions. <i>The Lancet Child and Adolescent Health</i> , 2019, 3, 725-733.	2.7	23
106	Patient-reported wellbeing and clinical disease measures over time captured by multivariate trajectories of disease activity in individuals with juvenile idiopathic arthritis in the UK: a multicentre prospective longitudinal study. <i>Lancet Rheumatology, The</i> , 2021, 3, e111-e121.	2.2	23
107	The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers. <i>Rheumatology</i> , 2015, 54, 1074-1079.	0.9	22
108	Long-term persistence with rituximab in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2018, 57, 1089-1096.	0.9	22

#	ARTICLE	IF	CITATIONS
109	The predictors of and reasons for non-adherence in an observational cohort of patients with rheumatoid arthritis commencing methotrexate. <i>Rheumatology</i> , 2020, 59, 213-223.	0.9	22
110	What is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis?. <i>Arthritis Research and Therapy</i> , 2016, 18, 282.	1.6	21
111	Prediction of response of methotrexate in patients with rheumatoid arthritis using serum lipidomics. <i>Scientific Reports</i> , 2021, 11, 7266.	1.6	21
112	Incidence and prevalence of juvenile idiopathic arthritis in the United Kingdom, 2000â€“2018: results from the Clinical Practice Research Datalink. <i>Rheumatology</i> , 2022, 61, 2548-2554.	0.9	21
113	Consistency and Utility of Data Items Across European Rheumatoid Arthritis Clinical Cohorts and Registers. <i>Arthritis Care and Research</i> , 2015, 67, 1219-1229.	1.5	20
114	Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure: results from The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Rheumatology</i> , 2018, 57, 1533-1540.	0.9	20
115	Short-term outcomes in patients with systemic juvenile idiopathic arthritis treated with either tocilizumab or anakinra. <i>Rheumatology</i> , 2019, 58, 94-102.	0.9	20
116	Harnessing repeated measurements of predictor variables for clinical risk prediction: a review of existing methods. <i>Diagnostic and Prognostic Research</i> , 2020, 4, 9.	0.8	20
117	Understanding Refractory Rheumatoid Arthritis: Implications for a Therapeutic Approach. <i>Drugs</i> , 2020, 80, 849-857.	4.9	20
118	Detection and evaluation of a drug safety signal concerning pancreatic cancer: lessons from a joint approach of three European biologics registers. <i>Rheumatology</i> , 2011, 50, 146-151.	0.9	18
119	Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis. <i>Lancet, The</i> , 2015, 385, S48.	6.3	18
120	Nonserious Infections in Patients With Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 1800-1809.	2.9	18
121	Predictors of presenteeism, absenteeism and job loss in patients commencing methotrexate or biologic therapy for rheumatoid arthritis. <i>Rheumatology</i> , 2020, 59, 2908-2919.	0.9	17
122	Prevalence and predictors of adverse events with methotrexate mono- and combination-therapy for rheumatoid arthritis: a systematic review. <i>Rheumatology</i> , 2021, 60, 4001-4017.	0.9	17
123	Association Between Ischemic Stroke and Tumor Necrosis Factor Inhibitor Therapy in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1337-1345.	2.9	16
124	Demyelinating Events Following Initiation of Anti-TNF $\pm$ Therapy in the British Society for Rheumatology Biologics Registry in Rheumatoid Arthritis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	16
125	Risk of <i>Pneumocystis jirovecii</i> pneumonia in patients with rheumatoid arthritis treated with inhibitors of tumour necrosis factor $\pm$ : results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis: Table 1. <i>Rheumatology</i> , 2016, 55, 1336-1337.	0.9	15
126	Detection of anti-drug antibodies using a bridging ELISA compared with radioimmunoassay in adalimumab-treated rheumatoid arthritis patients with random drug levels. <i>Rheumatology</i> , 2016, 55, 2050-2055.	0.9	14



#	ARTICLE	IF	CITATIONS
127	Mortality rates are increased in patients with systemic juvenile idiopathic arthritis. Archives of Disease in Childhood, 2017, 102, 206.2-207.	1.0	14
128	The prioritization of symptom beliefs over illness beliefs: The development and validation of the Pain Perception Questionnaire for Young People. British Journal of Health Psychology, 2018, 23, 68-87.	1.9	14
129	The influence of TNF inhibitors on dementia incidence in patients with rheumatoid arthritis; an analysis from the BSRBR. International Journal of Geriatric Psychiatry, 2018, 33, 556-558.	1.3	13
130	Impact of TNF inhibitor therapy on joint replacement rates in rheumatoid arthritis: a matched cohort analysis of BSRBR-RA UK registry data. Rheumatology, 2019, 58, 1168-1175.	0.9	13
131	Not all moderate disease is the same – Identification of disability trajectories among patients with rheumatoid arthritis and moderate disease activity. PLoS ONE, 2019, 14, e0215999.	1.1	13
132	Rates and predictors of methotrexate-related adverse events in patients with early rheumatoid arthritis: results from a nationwide UK study. Rheumatology, 2022, 61, 3930-3938.	0.9	13
133	The risk of uveitis in patients with JIA receiving etanercept: the challenges of analysing real-world data. Rheumatology, 2020, 59, 1391-1397.	0.9	12
134	EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatology. Annals of the Rheumatic Diseases, 2022, 81, 780-785.	0.5	12
135	Outcomes of SARS-CoV-2 infection among children and young people with pre-existing rheumatic and musculoskeletal diseases. Annals of the Rheumatic Diseases, 2022, 81, 998-1005.	0.5	12
136	The role of the British society for rheumatology biologics register (BSRBR) and the NICE guidelines for anti - TNF therapy. Musculoskeletal Care, 2003, 1, 58-64.	0.6	11
137	Growth in children and adolescents with juvenile idiopathic arthritis over 2 years of treatment with etanercept: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. Rheumatology, 2015, 54, 1279-1285.	0.9	11
138	The BSRBR-RA at 15 years. Rheumatology, 2016, 55, 2093-2095.	0.9	11
139	Prevalence and course of lower limb disease activity and walking disability over the first 5 years of juvenile idiopathic arthritis: results from the childhood arthritis prospective study. Rheumatology Advances in Practice, 2018, 2, rky039.	0.3	11
140	Methotrexate persistence and adverse drug reactions in patients with juvenile idiopathic arthritis. Rheumatology, 2019, 58, 1453-1458.	0.9	11
141	COVID-19 Global Rheumatology Alliance Registry, anti-IL-6 therapy, shared decision-making and patient outcomes. Response to: –Correspondence on –Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry” by Gianfrancesco et al. Compassionate use of tocilizumab in severe COVID-19 with hyperinflammation prior to advent of clinical trials – a real-world district general hospital experience” by K. Annals of the Rheumatic Diseases, 2020. , annrheumdis-2020-218713.	0.5	11
142	Changes in the illness perceptions of patients with rheumatoid arthritis over the first year of methotrexate therapy. Rheumatology, 2021, 60, 2355-2365.	0.9	11
143	Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatment. Arthritis Research and Therapy, 2021, 23, 80.	1.6	11
144	The predictive value of serum S100A9 and response to etanercept is not confirmed in a large UK rheumatoid arthritis cohort. Rheumatology, 2017, 56, kew387.	0.9	10

#	ARTICLE	IF	CITATIONS
145	Effectiveness of sequential biologic and targeted disease modifying anti-rheumatic drugs for rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, 4678-4686.	0.9	10
146	Previously reported <i>PDE3A</i> genetic variant does not correlate with anti-TNF response in a large UK rheumatoid arthritis cohort. <i>Pharmacogenomics</i> , 2016, 17, 715-720.	0.6	9
147	Pregnancy outcomes in women with rheumatoid arthritis ever treated with rituximab. <i>Rheumatology</i> , 2017, 56, kew493.	0.9	9
148	Latent Class Trajectory Modeling of 2-Component Disease Activity Score in 28 Joints Identifies Multiple Rheumatoid Arthritis Phenotypes of Response to Biologic Disease-Modifying Antirheumatic Drugs. <i>Arthritis and Rheumatology</i> , 2020, 72, 1632-1642.	2.9	9
149	Burden of comorbid conditions in children and young people with juvenile idiopathic arthritis: a collaborative analysis of 3 JIA registries. <i>Rheumatology</i> , 2022, 61, 2524-2534.	0.9	9
150	Nothing about us without us: involving patient collaborators for machine learning applications in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1505-1510.	0.5	9
151	COVID-19 in Pregnant Women With Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance. <i>Journal of Rheumatology</i> , 2022, 49, 110-114.	1.0	9
152	When TNF inhibitors fail in RA—weighing up the options. <i>Nature Reviews Rheumatology</i> , 2014, 10, 262-264.	3.5	8
153	Effectiveness and safety of TNF inhibitors in adults with juvenile idiopathic arthritis. <i>RMD Open</i> , 2016, 2, e000273.	1.8	8
154	Long-term outcomes of patients who rate symptoms of rheumatoid arthritis as “satisfactory”. <i>Rheumatology</i> , 2020, 59, 1853-1861.	0.9	8
155	Early response to anti-TNF predicts long-term outcomes including sustained remission: an analysis of the BSRBR-RA. <i>Rheumatology</i> , 2020, 59, 1709-1714.	0.9	8
156	Response to Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis by GyÅrri et al. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e88-e88.	0.5	8
157	Assessing the safety of biologic therapies in rheumatoid arthritis: the challenges of study design. <i>Journal of rheumatology Supplement, The</i> , 2005, 72, 48-50.	2.2	7
158	Investigating CD11c expression as a potential genomic biomarker of response to TNF inhibitor biologics in whole blood rheumatoid arthritis samples. <i>Arthritis Research and Therapy</i> , 2015, 17, 359.	1.6	6
159	Translating research into clinical practice: quality improvement to halve non-adherence to methotrexate. <i>Rheumatology</i> , 2021, 60, 125-131.	0.9	6
160	EULAR COVID-19 registry: lessons learnt and future considerations. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1110-1115.	0.5	6
161	Abatacept in the long-term treatment of rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2012, 8, 231-234.	1.3	5
162	Prediction of response and adverse events to methotrexate treatment in patients with rheumatoid arthritis. <i>International Journal of Clinical Rheumatology</i> , 2012, 7, 559-567.	0.3	5

#	ARTICLE	IF	CITATIONS
163	Predicting Remission Remains a Challenge in Patients with Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2019, 46, 552-554.	1.0	5
164	Real world data in rheumatology. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, S22-S24.	1.6	5
165	Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry by Gianfrancesco et al. Disease activity, rather than glucocorticoid therapy, may be associated with COVID-19 severity in patients with rheumatic musculoskeletal diseases by Giollo et al. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e223-e223.	0.5	5
166	Do people with rheumatoid arthritis maintain their physical activity level at treatment onset over the first year of methotrexate therapy?. <i>Rheumatology</i> , 2021, 60, 4633-4642.	0.9	5
167	How effective are JAK-inhibitors? Perspectives from clinical trials and real-world studies. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 207-220.	1.3	5
168	Exploring the disparity between inflammation and disability in the 10-year outcomes of people with rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, 4687-4701.	0.9	5
169	Juvenile-onset inflammatory arthritis: a study of adolescents' beliefs about underlying cause. <i>Rheumatology</i> , 2012, 51, 2239-2245.	0.9	4
170	P2. Incidence and Severity of Myocardial Infarction in Subjects Receiving Anti-Tumour Necrosis Factor Drugs for Rheumatoid Arthritis: Results from Linking the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis and Myocardial Ischaemia National Audit Project. <i>Rheumatology</i> , 2014, 53, i34-i35.	0.9	4
171	Analysing and reporting of observational data: a systematic review informing the EULAR points to consider when analysing and reporting comparative effectiveness research with observational data in rheumatology. <i>RMD Open</i> , 2021, 7, e001818.	1.8	4
172	Pharmacogenetics of TNF inhibitor response in rheumatoid arthritis utilizing the two-component disease activity score. <i>Pharmacogenomics</i> , 2020, 21, 1151-1156.	0.6	3
173	Pre-defined gene co-expression modules in rheumatoid arthritis transition towards molecular health following anti-TNF therapy. <i>Rheumatology</i> , 2022, 61, 4935-4944.	0.9	3
174	PP3. Standardized mortality rates are increased in patients with severe JIA. <i>Rheumatology</i> , 2015, 54, ii6-ii6.	0.9	2
175	Response to: "Does the risk of lymphoma in patients with RA treated with TNF inhibitors differ according to the histological subtype and the type of TNF inhibitor?" by Nocturne et al. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, e4-e4.	0.5	2
176	Common Functional Ability Score for Young People With Juvenile Idiopathic Arthritis. <i>Arthritis Care and Research</i> , 2021, 73, 947-954.	1.5	2
177	Response to: "Correspondence on "Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry" by Arnaud and Devilliers. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e114-e114.	0.5	2
178	Response to: "Correspondence on "Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry" by Rosenbaum et al. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e139-e139.	0.5	2
179	The Role of Age in Delays to Rheumatological Care in Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2022, 49, 1037-1041.	1.0	2
180	Are patients with RA at increased risk of malignancy?. <i>Nature Clinical Practice Rheumatology</i> , 2008, 4, 632-633.	3.2	1

#	ARTICLE	IF	CITATIONS
181	Cervical screening uptake and rates of cervical dysplasia in the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Rheumatology</i> , 2019, 59, 559-567.	0.9	1
182	AB0434â€¦EARLY EXPERIENCE WITH JAK INHIBITOR PRESCRIBING IN THE UK: RESULTS FROM THE BRITISH SOCIETY FOR RHEUMATOLOGY BIOLOGICS REGISTER FOR RHEUMATOID ARTHRITIS (BSRBR-RA). , 2019, , .		1
183	What can rheumatology expect from real-world data?. <i>Rheumatology</i> , 2020, 59, 12-13.	0.9	1
184	O27â€¦Early experience with JAK inhibitor prescribing in the UK: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA). <i>Rheumatology</i> , 2020, 59, .	0.9	1
185	BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. <i>Rheumatology</i> , 2010, , .	0.9	1
186	OA19â€¦Successes and challenges in harmonising four national juvenile idiopathic arthritis cohorts: an example from CLUSTER consortium. <i>Rheumatology</i> , 2022, 61, .	0.9	1
187	P189â€¦A longitudinal study of psychological predictors of response to adalimumab in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, .	0.9	1
188	Comment on: Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register: reply. <i>Rheumatology</i> , 2010, 49, 1794-1794.	0.9	0
189	O23.â€¦The Influence of Anti-TNF or Rituximab on Cancer Incidence in Patients with Rheumatoid Arthritis who Have Had a Prior Malignancy. <i>Rheumatology</i> , 2014, 53, i38-i38.	0.9	0
190	39.â€¦Non-Differential Reporting of Myocardial Infarction to a National Observational Drug Safety Study Using Linked Data: Linkage of the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis and the Myocardial Ischaemia National Audit Project. <i>Rheumatology</i> , 2014, 53, i70-i70.	0.9	0
191	221.â€¦Risk of Cancer in Patients with Severe Psoriatic Arthritis Requiring Tumour Necrosis Factor Alpha Inhibition. <i>Rheumatology</i> , 0, , .	0.9	0
192	274.â€¦Factors Associated with Choice of First Biologic Among Children with Juvenile Idiopathic Arthritis: A Combined Analysis from Two UK Paediatric Biologic Registers. <i>Rheumatology</i> , 2015, , .	0.9	0
193	220.â€¦Predicting Successful Long-Term Treatment with Tumour Necrosis Factor Alpha Inhibitors in Patients with Psoriatic Arthritis. <i>Rheumatology</i> , 0, , .	0.9	0
194	O10.â€¦Risk and Characteristics of Drug-Induced Lupus in Patients Exposed to Tumour Necrosis Factor-Î± Inhibitor Therapy: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Rheumatology</i> , 2015, , .	0.9	0
195	O32â€¦Estimates of Inactive Disease are Strongly Influenced by Outcome Definition in a Prospective Cohort of Patients with Juvenile Idiopathic Arthritis. <i>Rheumatology</i> , 0, , .	0.9	0
196	O50â€¦High Frequency of Anti-Drug Antibodies and Correlation of Low Random Drug Levels with Lack of Efficacy in Certolizumab Pegol-Treated Patients with Rheumatoid Arthritis. <i>Rheumatology</i> , 0, , .	0.9	0
197	Does sex or ethnicity impact anti-tumour necrosis factor agent use in rheumatoid arthritis?. <i>Rheumatology</i> , 2017, 56, kew466.	0.9	0
198	159.â€¦THE IMPORTANCE OF ACHIEVING CLINICAL RESPONSE TO TREATMENT AND CHANGES IN PHYSICAL ABILITY AND QUALITY OF LIFE ON WORKER PRODUCTIVITY OUTCOMES IN RHEUMATOID ARTHRITIS: RESULTS FROM THE BRITISH SOCIETY FOR RHEUMATOLOGY BIOLOGICS REGISTER FOR RHEUMATOID ARTHRITIS. <i>Rheumatology</i> , 2017, 56, .	0.9	0

#	ARTICLE	IF	CITATIONS
199	O54.â€fTREATMENT DECISIONS FOLLOWING A DIAGNOSIS OF CANCER DURING TUMUOR NECROSIS FACTOR INHIBITOR TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS. Rheumatology, 2017, 56, .	0.9	0
200	49.â€fBiological treatments for adults with Juvenile Idiopathic Arthritis: a clear need for improved access to targeted education and training. Rheumatology, 2017, 56, .	0.9	0
201	I77.â€fQUALITY VERSUS FRAUD IN CLINICAL RESEARCH: HOW RESEARCH METHODOLOGY CAN INFLUENCE RESEARCH CONCLUSIONS. Rheumatology, 2017, 56, .	0.9	0
202	O86â€fA longitudinal analysis of prevalence of sustained remission and low disease activity in rheumatoid arthritis patients treated with anti-tumour necrosis factor: an analysis of the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology, 2018, 57, .	0.9	0
203	P41â€fA UK study: vocational experiences of young adults with juvenile idiopathic arthritis. Rheumatology, 2018, 57, .	0.9	0
204	227â€fPredictors of presenteeism and absenteeism in patients commencing treatment with methotrexate monotherapy or biologic therapy for rheumatoid arthritis. Rheumatology, 2018, 57, .	0.9	0
205	e111â€fPatterns of the patient acceptable symptom state over 12 months following the initiation of methotrexate therapy in patients with rheumatoid arthritis, and the association between these patterns and disability and disease activity. Rheumatology, 2018, 57, .	0.9	0
206	P33â€fFirst diagnosis of uveitis is not higher among juvenile idiopathic arthritis patients receiving etanercept compared to methotrexate. Rheumatology, 2018, 57, .	0.9	0
207	O89â€fThe association between poor prognostic factors at methotrexate initiation and disease activity and disability over one year: results from the Rheumatoid Arthritis Medication Study. Rheumatology, 2018, 57, .	0.9	0
208	212â€fMultimorbidity is associated with increased disability but lower disease activity over time in patients with RA: results from the BSRBR-RA. Rheumatology, 2018, 57, .	0.9	0
209	296â€fUK survey of young adults with juvenile idiopathic arthritis and their vocational experiences. Rheumatology, 2018, 57, .	0.9	0
210	e122â€fClinical phenotypes of patients with rheumatoid arthritis who identify as in a patient acceptable symptom state at methotrexate initiation and a comparison of the outcome of these phenotypes over 12 months. Rheumatology, 2018, 57, .	0.9	0
211	243â€fLongâ€term risk of serious infections in patients with rheumatoid arthritis treated with rituximab: five year data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBRâ€RA). Rheumatology, 2018, 57, .	0.9	0
212	O29â€fPredicting remission from one year following initial presentation in a multicentre inception cohort of patients with juvenile idiopathic arthritis. Rheumatology, 2018, 57, .	0.9	0
213	A UK study: vocational experiences of young adults with juvenile idiopathic arthritis. Pediatric Rheumatology, 2019, 17, 54.	0.9	0
214	O19â€fThe association of biologic drug-levels with infection risk: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA). Rheumatology, 2019, 58, .	0.9	0
215	O23â€fUsing big data in the design and validation of a simulation of the healthcare system for patients with inflammatory rheumatic disease: results from the SiMSK study. Rheumatology, 2019, 58, .	0.9	0
216	O24â€fThe impact of early referral and lowering clinical thresholds of biologic access on the disease course and costs in RA: results from the SiMSK study. Rheumatology, 2019, 58, .	0.9	0

#	ARTICLE	IF	CITATIONS
217	SAT0062â€¦STRATIFIED MEDICINE FOR RHEUMATOID ARTHRITIS: PREDICTING RESPONSE TO BIOLOGIC THERAPY USING IMMUNE CELL SIGNATURES. , 2019, , .		0
218	FRI0674â€¦THE ASSOCIATION BETWEEN JOINT EROSIONS PLUS AUTOANTIBODY POSITIVITY AT INITIATION OF METHOTREXATE OR BIOLOGIC THERAPY FOR RHEUMATOID ARTHRITIS AND DISEASE ACTIVITY AND DISABILITY OVER ONE YEAR. , 2019, , .		0
219	SAT0141â€¦FREQUENCY AND REASONS FOR SWITCHING BACK TO BIOLOGIC ORIGINATOR FOLLOWING INITIAL SWITCH TO BIOLOGIC BIOSIMILAR. , 2019, , .		0
220	FRI0546â€¦TRAJECTORIES OF DISEASE ACTIVITY OVER THE FIRST THREE YEARS FOLLOWING JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSIS. , 2019, , .		0
221	THU0668â€¦THE ASSOCIATION BETWEEN ANTI-CCP TITRE LEVEL AND DISEASEACTIVITY AND DISABILITY OVER ONE YEAR FOLLOWING THE INITIATION OF METHOTREXATE OR BIOLOGIC THERAPY FOR ANTI-CCP+ RHEUMATOID ARTHRITIS. , 2019, , .		0
222	P212â€¦The effect of body weight in response to subcutaneous tocilizumab in patients with RA. Rheumatology, 2020, 59, .	0.9	0
223	P228â€¦Risk of sinusitis in patients with rheumatoid arthritis: association with different treatment strategies. Rheumatology, 2020, 59, .	0.9	0
224	O06â€¦Baseline predictors of methotrexate-related adverse events in methotrexate-naïve patients with RA. Rheumatology, 2021, 60, .	0.9	0
225	O32â€¦Serious infection with tocilizumab compared to TNF-inhibitors and other bDMARDs in rheumatoid arthritis patients: does line of therapy matter?. Rheumatology, 2021, 60, .	0.9	0
226	No evidence that genetic predictors of susceptibility predict changes in core outcomes in JIA. Rheumatology, 2022, , .	0.9	0
227	Biologic and advanced therapy registers in rheumatoid arthritis. Medicine, 2022, , .	0.2	0
228	P090â€¦Clinical prediction models for methotrexate treatment outcomes in rheumatoid arthritis patients: a review of existing models and summary of their limitations. Rheumatology, 2022, 61, .	0.9	0
229	OA14â€¦Outcomes after switching from etanercept originator to its biosimilar (SB4) for the treatment of rheumatoid arthritis. Rheumatology, 2022, 61, .	0.9	0
230	P200â€¦Combining protein quantitative trait and genetic risk score analysis to identify biomarkers of treatment response to TNFi in patients with rheumatoid arthritis. Rheumatology, 2022, 61, .	0.9	0
231	OA14bâ€¦Etanercept originator versus its biosimilar (SB4) for the treatment of rheumatoid arthritis. Are they truly similar?. Rheumatology, 2022, 61, .	0.9	0
232	OA21â€¦Continuing specialist care beyond age 16 in young people with juvenile idiopathic arthritis: a descriptive study using electronic health records in England. Rheumatology, 2022, 61, .	0.9	0
233	P068â€¦Monitoring of methotrexate blood toxicity during the COVID-19 pandemic for patients with rheumatoid arthritis: data from the Greater Manchester Care Record. Rheumatology, 2022, 61, .	0.9	0
234	OA01â€¦Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. Rheumatology, 2022, 61, .	0.9	0

#	ARTICLE	IF	CITATIONS
235	OA24â€fPredicting drug immunogenicity to tumour necrosis factor inhibitors in patients with rheumatoid arthritis. Rheumatology, 2022, 61, .	0.9	0
236	OA15â€fDrivers of change in four and two component disease activity scores after etanercept treatment, in a multi-centre cohort of patients with established rheumatoid arthritis. Rheumatology, 2022, 61, .	0.9	0
237	P162â€fSocio-economic status in patients with juvenile idiopathic arthritis in the United Kingdom. Rheumatology, 2022, 61, .	0.9	0
238	OA16â€fTherapeutic certolizumab pegol drug levels to achieve good EULAR response in patients with rheumatoid arthritis: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS) cohort. Rheumatology, 2022, 61, .	0.9	0
239	Is time a healer? How quality of life changes over time reported by parents of children and young people with Juvenile Idiopathic Arthritis. Rheumatology, 0, , .	0.9	0